Meet the Pacific Bluefin Tuna, a fish prized by the world’s greatest sushi restaurants. Its marbled fat, buttery texture, and umami flavor see it command up to $80 per pound at wholesale markets and $20 per piece for the premium Otoro grade at notable sushi restaurants.

But the Pacific Bluefin Tuna is rare, comprising less than 1% of the global tuna catch. Today, it faces critical supply-and-demand issues.

The challenge is how to meet the growing demand. Existing options fall short:

Worldwide demand for seafood continues to grow reaching roughly 45 pounds per person each year.

With wild fishing volumes remaining flat since the 1990s, aquaculture has filled the gap for many species, surpassing wild catch for the first time in 2022.

The concentration of fish with aquaculture, though, leads to high levels of ocean pollution, increased rates of disease, extensive use of antibiotics, and destruction of natural habitats.

The Finless method produces a premium, clean, versatile protein. The initial $2B bluefin tuna market is just the beginning. The technology is adaptable, allowing extension to the wider $40B+ tuna market and even the full $360B+ seafood market.

To meet future demand, Finless is developing a network of commercial food partners to both produce the sustainable fish and distribute it to their markets.

The nutritional components and cell profile have long made fish a desirable ingredient for health supplements and functional foods.

Tuna’s combination of high protein, lean muscle mass, and essential omega-3 fatty acids place it near the top of that list.

The flexibility of Finless technology to produce specific collagen, protein, and muscle cells will open other markets worth billions of dollars.

Tuna collagen is rich in amino acids key to connective tissue making it an excellent ingredient for both the skin/beauty and joint health categories.

The high density, high quality, and easy digestibility of tuna protein also make it an excellent candidate for functional foods especially those that want to maintain a low calorie profile.

Development of Finless products begins with a one-of-a-kind Pacific Bluefin Tuna cell line, the highest grade of tuna.

This proprietary method is capable of producing food-grade sushi as well as collagen, protein, muscle, and fat cells. This cell line also provides the building blocks for future Finless products.

The tuna sashimi product has been produced and Finless is engaging with the FDA for regulatory review and approval. Completion of the review is expected in 2027.

Finless proprietary IP will allow for the rapid development of other high-value marine species, including salmon. Utilizing fresh fish tissue creates a high-quality cell line.  Once established, that cell line can be used for ongoing high-volume production.

The FDA review is an inflection point 

Approval opens the door to immediate commercialization, much as one sees when a new pharmaceutical is approved.

It also kicks off a multi-phase roadmap for expansion into various product categories and international markets.

Finless is aligning resources for this expansion plan now. The company has established relationships with major food distributors. Discussions are also underway for a regional production network.

To prepare for growth, Finless is also actively working with Cultivate at Scale (CAS), a leader in cell culture technology, to refine its commercial production process.

Thanks to their validated science and proprietary technology with the potential for expansion to large addressable markets, Finless has attracted venture capital funding with connections to key markets:

The Finless leadership team possesses deep biotechnology expertise and a vision for the future of sustainable seafood.

The work of CEO Brandon Chen includes the discovery of anti-cancer drugs plus experience in the regulatory submission and approval process.

Co-founder and Chief Science Officer Brian Wyrwas established the proprietary fish cell lines for Finless, including Pacific bluefin tuna.

Co-founder Michael Selden brings expertise in Molecular Biology and was named to Forbes 30 Under 30 - Social Impact in 2021.

Finless Foods: The Future of Seafood, Without the Catch

Finless Foods is a pioneer in developing high-quality seafood by producing cultivated bluefin tuna rather than harvesting it from the ocean, and doing so without mercury, microplastics, or environmental harm.

• A sustainable solution to the growing demand for high-quality seafood
• A value inflection point upon FDA approval
• An adaptable process technology for expansion to functional foods and supplement markets

As a lifelong surfer, I'm passionate about planet and ocean health. Join us to bring sustainable, cultivated seafood to market and create a future free of environmental harm.

- Brandon Chen, Co-Founder & CEO